Carol Ravenscroft

Llamau Ltd. provides housing services to homeless women and youth. The firm's services include housing support, training and education, advising, family mediation, and mental health support. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom.

Llamau Ltd. provides housing services to homeless women and youth. The firm's services include housing support, training and education, advising, family mediation, and mental health support. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom.

Llamau Ltd. provides housing services to homeless women and youth. The firm's services include housing support, training and education, advising, family mediation, and mental health support. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom.

Llamau Ltd. provides housing services to homeless women and youth. The firm's services include housing support, training and education, advising, family mediation, and mental health support. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom.

Llamau Ltd. provides housing services to homeless women and youth. The firm's services include housing support, training and education, advising, family mediation, and mental health support. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom.

Llamau Ltd. provides housing services to homeless women and youth. The firm's services include housing support, training and education, advising, family mediation, and mental health support. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom.

Drive is a non-profit LLC that focuses on discovering and developing antiviral drugs for emerging infections, pandemic threats, and biodefense. The non-profit company is based in Nantgarw, UK. The British company operates like an early stage biotechnology company and applies focus and industry development expertise to efficiently translate discoveries to address viruses of concern. The company is unique in that it brings industry expertise to the assets of a leading research university to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. The company was founded in 1983. Rhian Jones has been the CEO of the company since 2018.